News

Mirati and ZoBio Collaborate to Advance Targeted Oncology Programs

Mirati Therapeutics has selected ZoBio to provide fragment-based screening, biophysical compound characterization and structural biology for several oncology targets. In this arrangement, ZoBio screens its fragment library using both its proprietary Target Immobilized NMR Screening and SPR capabilities. Subsequently hit analogs are characterized by a biophysics-based cascade tailored to select molecules with the desired Mode…